MA44067A - Anticorps dirigés contre la quétiapine et utilisation associée - Google Patents

Anticorps dirigés contre la quétiapine et utilisation associée

Info

Publication number
MA44067A
MA44067A MA044067A MA44067A MA44067A MA 44067 A MA44067 A MA 44067A MA 044067 A MA044067 A MA 044067A MA 44067 A MA44067 A MA 44067A MA 44067 A MA44067 A MA 44067A
Authority
MA
Morocco
Prior art keywords
quetiapine
directed against
antibodies directed
associated use
antibodies
Prior art date
Application number
MA044067A
Other languages
English (en)
Inventor
Linda Colt
Thomas R Decory
Matthew G Donahue
Yong Gong
Eric Hryhorenko
Bart M Remmerie
Rhys Salter
Banumathi Sankaran
Theresa Tubbs
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA44067A publication Critical patent/MA44067A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044067A 2015-12-17 2016-12-15 Anticorps dirigés contre la quétiapine et utilisation associée MA44067A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268924P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
MA44067A true MA44067A (fr) 2018-10-24

Family

ID=57799801

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044067A MA44067A (fr) 2015-12-17 2016-12-15 Anticorps dirigés contre la quétiapine et utilisation associée

Country Status (8)

Country Link
US (2) US10435478B2 (fr)
EP (1) EP3390455A1 (fr)
JP (1) JP6994461B2 (fr)
CN (1) CN108368180B (fr)
AU (1) AU2016370853A1 (fr)
CA (1) CA3008812A1 (fr)
MA (1) MA44067A (fr)
WO (1) WO2017106508A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
CA2882597C (fr) * 2012-08-21 2020-04-14 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de quetiapine et leur utilisation
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
WO2017106508A1 (fr) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN116354904B (zh) * 2023-04-26 2023-08-01 北京丹大生物技术有限公司 一种喹硫平衍生物半抗原、抗原、抗喹硫平抗体及其应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
EP0560411B1 (fr) 1987-04-27 2000-07-26 Unilever N.V. Essais de liaisons spécifiques
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
DE69329887T2 (de) 1992-05-29 2001-05-23 Eli Lilly And Co., Ltd. Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
EP0804580B1 (fr) 1994-06-10 2008-10-08 Oklahoma Medical Research Foundation Anticorps recombine se liant au calcium contre la proteine c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
ATE380818T1 (de) 2002-03-28 2007-12-15 Lilly Co Eli Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
CA2494109A1 (fr) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Therapies de combinaison antipsychotiques et compositions d'un antagoniste du recepteur d'alpha-2 adrenergique et d'un tranquillisant majeur antipsychotique atypique
ES2285227T3 (es) 2002-08-05 2007-11-16 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina.
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US7767683B2 (en) 2003-08-18 2010-08-03 H. Lundbeck A/S Hydrogen succinate salts of trans-4-((1R, 3S)-6-chloro-3-phenylindan-1-YL)-1,2,2-trimethylpiperazine and the use as a medicament
ES2335589T3 (es) 2003-09-23 2010-03-30 Fermion Oy Preparacion de quetiapina.
NZ546834A (en) 2003-10-01 2010-03-26 Adolor Corp Spirocyclic heterocyclic derivatives and methods of their use
ZA200602347B (en) 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
DE602004024236D1 (en) 2003-12-12 2009-12-31 Inverness Medical Switzerland Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (fr) 2004-04-26 2007-07-18 Takami Matsuyama Médicament thérapeutique contenant un anticorps monoclonal anti récepteur béta de folate (fr-beta)
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
US8394790B2 (en) 2006-10-25 2013-03-12 Ramot At Tel-Aviv University Ltd. Psychotropic agents having glutamate NMDA activity
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
WO2008082979A2 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Essai diagnostique pour la détection d'une molécule ou d'un médicament dans du sang entier
CN101091700B (zh) 2007-07-03 2011-06-08 上海现代药物制剂工程研究中心有限公司 富马酸喹硫平缓控释制剂组合物及其制备用途
RU2010116351A (ru) 2007-09-27 2012-05-20 Новартис АГ (CH) Мониторинг лекарственных средств
CN102131519B (zh) 2008-07-21 2016-01-13 前体生物药物股份公司 诊断抗体测定
EP2331088A4 (fr) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd Compositions et procédés de traitement de troubles psychiatriques
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
EP2350077B1 (fr) 2008-10-14 2016-01-27 Entasis Therapeutics Limited Composés hétéroaromatiques spirocycliques fusionnés pour traiter les infections bactériennes
EP2347015A4 (fr) 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv Procédés de traitement d'une psychose et de la schizophrénie basés sur des polymorphismes du gène erbb4
EP2194048A1 (fr) 2008-12-02 2010-06-09 Dirk Sartor Esters de nitrate pour le traitement de maladies vasculaires et métaboliques
US20100203129A1 (en) 2009-01-26 2010-08-12 Egalet A/S Controlled release formulations with continuous efficacy
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
CA2889457C (fr) 2009-12-31 2016-06-28 Kempharm, Inc. Conjugues d'acides amines de quetiapine, procede de fabrication et d'utilisation de ceux-ci
TR201900067T4 (tr) 2010-03-11 2019-02-21 Kempharm Inc Ketiyapinin yağ asidi konjugatları, bunların yapılmasına ve kullanılmasına yönelik proses.
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (fr) 2010-06-15 2011-12-22 The Regents Of The University Of California Procédé et dispositif pour la détection d'analytes
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
EP2790734B1 (fr) 2011-12-15 2019-02-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
EA201590381A1 (ru) 2012-08-16 2015-07-30 Янссен Фармацевтика Нв Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
WO2014031587A1 (fr) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptènes de l'olanzipine
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
CA2882597C (fr) * 2012-08-21 2020-04-14 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de quetiapine et leur utilisation
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
CA2882596C (fr) 2012-08-21 2019-05-14 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre l'olanzapine et leur utilisation
ES2645433T3 (es) 2012-08-21 2017-12-05 Janssen Pharmaceutica, N.V. Haptenos de quetiapina para su uso en inmunoensayos
TR201809424T4 (tr) 2012-08-21 2018-07-23 Janssen Pharmaceutica Nv Risperidon ve paliperidon haptenleri.
PT2888258T (pt) 2012-08-21 2019-08-21 Janssen Pharmaceutica Nv Hapteno de paliperidona
JP6339569B2 (ja) 2012-08-21 2018-06-06 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンへの抗体及びその使用
EP2888234B1 (fr) 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptènes d'aripiprazole et leur utilisation dans des dosages immunologiques
EP2888287A4 (fr) 2012-08-21 2016-04-20 Ortho Clinical Diagnostics Inc Anticorps dirigés contre des haptènes de palipéridone et leur utilisation
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017106508A1 (fr) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
US10444250B2 (en) * 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Also Published As

Publication number Publication date
US20170176474A1 (en) 2017-06-22
WO2017106508A1 (fr) 2017-06-22
CN108368180B (zh) 2022-07-26
EP3390455A1 (fr) 2018-10-24
CN108368180A (zh) 2018-08-03
CA3008812A1 (fr) 2017-06-22
AU2016370853A1 (en) 2018-06-07
US11104742B2 (en) 2021-08-31
US10435478B2 (en) 2019-10-08
JP6994461B2 (ja) 2022-02-04
JP2019504014A (ja) 2019-02-14
US20200002438A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MA49823A (fr) Anticorps dirigés contre pd-l1
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
IL289766A (en) tfpi inhibitory antibodies and their uses
DK3177259T3 (da) Forbindelses- og beholdersystem
DK3288865T3 (da) Opbevarings- og hentningssystem
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
MA47472A (fr) Anticorps
JP2017529290A5 (ja) 粉末コンテナおよびそれを用いたシステム
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
HK1255331A1 (zh) 抗pcsk9抗體及其應用
MA44067A (fr) Anticorps dirigés contre la quétiapine et utilisation associée
DK3379690T3 (da) Hurtigopladningsfremgangsmåde og -system
UA38793S (uk) Акумуляторна батарея
DK3101760T3 (da) Opladningsfremgangsmåde og system
DK3377634T3 (da) Bakteriebaseret proteinafgivelse
MA42843A (fr) Anticorps anti-cd115
ZA201605760B (en) Immobilized proteins and use thereof
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
MA44056A (fr) Anticorps anti-rispéridone et leur utilisation
MA49905A (fr) Polyesteramines et polyesterquats
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf